Form 4: Syndax Pharmaceuticals Director Jennifer Jarrett Reports Stock Award and Disposal

Director Jennifer Jarrett reports the acquisition of 25,000 shares of Syndax Pharmaceuticals stock through a restricted stock unit award and the disposal of 90,000 shares.

Summary

• On February 5, 2025, Jennifer Jarrett, a director of Syndax Pharmaceuticals Inc., reported a transaction involving the company's common stock.
• Jarrett acquired 25,000 shares through a restricted stock unit (RSU) award at a price of $0.
• The RSUs vest one year from the grant date.
• The shares underlying the RSUs cannot be transferred or sold until separation from service, death, disability, or a change in control.
• Jarrett also disposed of 90,000 shares.
• Following these transactions, Jarrett directly owns 90,000 shares of Syndax Pharmaceuticals Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. The acquisition of RSUs is mildly positive, while the disposal of shares is mildly negative. The overall impact is likely minimal.

Positives

• The acquisition of shares through RSUs indicates a potential alignment of the director's interests with the long-term performance of the company.

Negatives

• The disposal of 90,000 shares could be interpreted negatively by investors, although the reason for the disposal is not disclosed.

Risks

• The transfer restrictions on the RSU shares could limit the director's ability to benefit from short-term gains in the stock price.
• The disposal of 90,000 shares could create downward pressure on the stock price if other insiders follow suit.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders. It provides transparency into the trading activities of company directors and officers, which can be useful for investors in assessing management's sentiment and potential future performance.

Stakeholder Impact

• Shareholders may be interested in the director's stock transactions as an indicator of confidence in the company's future prospects.

Key Dates